News
Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, ...
5h
TipRanks on MSNLava Therapeutics reports Q2 EPS (32c) vs. (31c) last year
Reports Q2 revenue $0 vs. $0 last year. As of June 30, Lava had cash, cash equivalents, and short-term investments of $56.2M vs. $76.6M as of ...
Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...
EMERYVILLE, Calif. (AP) — EMERYVILLE, Calif. (AP) — XOMA Royalty Corporation (XOMA) on Wednesday reported second-quarter net income of $9.2 million. On a per-share basis, the Emeryville, ...
Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently ...
15h
TipRanks on MSNXoma reports Q2 EPS 44c, consensus (15c)
Reports Q2 revenue $13.129M, consensus $9.39M. “We continue to add to our diversified portfolio of both early- and late-stage assets through ...
Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or ...
Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 ...
NasdaqGM:XOMA 1 Year Share Price vs Fair Value Explore XOMA Royalty's Fair Values from the Community and select ...
SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...
The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty Corporation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results